Literature DB >> 8807119

Cytokine expression in human cutaneous chronic graft-versus-host disease.

L A Ochs1, B R Blazar, J Roy, E B Rest, D J Weisdorf.   

Abstract

Although chronic graft-versus-host disease (GVHD) remains a frequent complication of bone marrow transplantation (BMT), the pathogenesis remains unclear. We examined the potential role of cytokines in mediating chronic GVHD. Skin samples from seven patients with cutaneous chronic GVHD, six post-BMT controls and six normal controls were evaluated by reverse transcription polymerase chain reaction for the proinflammatory cytokines interleukin-1 alpha (IL-1 alpha) and tumor necrosis factor-alpha (TNF-alpha), Th1-associated cytokines IL-2 and interferon-gamma (IFN-gamma), Th2-associated cytokines IL-4, IL-5 and IL-10, and fibrosis-associated cytokines platelet derived growth factor (PDGF) and transforming growth factor-beta (TGF-beta). IFN-gamma transcription was significantly more frequent in cutaneous chronic GVHD (86%) vs post-BMT and normal controls (17% (P = 0.03) and 0 (P = 0.005), respectively). IL-2 transcription was more frequent in chronic GVHD (28%) and post-BMT controls (50%) vs normal controls (17%). TNF-alpha mRNA was frequent in chronic GVHD (71%) and post-BMT controls (83%), but not significantly more than in normal controls (50%). Transcription of IL-1alpha, IL-4, IL-5 and IL-10 was infrequent in all three groups. PDGF and TGF-beta mRNA were detected in the majority of all samples. The frequent transcription of IFN-gamma in cutaneous chronic GVHD supports its potential role in mediating the associated tissue injury. While the cellular sources of these cytokines are uncertain, their expression and secretion in situ may propagate the cytotoxic cascade and perpetuate the tissue injury. Better understanding of the contribution of FN-gamma and other cytokines to the pathogenesis of chronic GVHD may allow the design of more specific and more effective therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807119

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  14 in total

1.  [Cutaneous graft-versus-host disease].

Authors:  S Karrer
Journal:  Hautarzt       Date:  2003-05       Impact factor: 0.751

2.  The isomorphic response in morphealike chronic graft-vs-host disease.

Authors:  Asha R Patel; Steven Z Pavletic; Maria L Turner; Edward W Cowen
Journal:  Arch Dermatol       Date:  2008-09

3.  Increased Th17/Treg ratio in chronic liver GVHD.

Authors:  F Malard; C Bossard; E Brissot; P Chevallier; T Guillaume; J Delaunay; J-F Mosnier; P Moreau; M Grégoire; B Gaugler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

4.  Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031.

Authors:  Jacob Rozmus; Kirk R Schultz; Kristin Wynne; Amina Kariminia; Preeti Satyanarayana; Mark Krailo; Stephan A Grupp; Andrew L Gilman; Frederick D Goldman
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-25       Impact factor: 5.742

Review 5.  Biomarkers in chronic graft-versus-host disease.

Authors:  Jacob Rozmus; Kirk R Schultz
Journal:  Expert Rev Hematol       Date:  2011-06       Impact factor: 2.929

6.  CD20, AIF-1, and TGF-beta in graft-versus-host disease: a study of mRNA expression in histologically matched skin biopsies.

Authors:  Julie M Wu; Christopher J Thoburn; Joshua Wisell; Evan R Farmer; Allan D Hess
Journal:  Mod Pathol       Date:  2010-02-26       Impact factor: 7.842

Review 7.  New approaches for preventing and treating chronic graft-versus-host disease.

Authors:  Stephanie J Lee
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

8.  c-Rel is an essential transcription factor for the development of acute graft-versus-host disease in mice.

Authors:  Yu Yu; Dapeng Wang; Kane Kaosaard; Chen Liu; Jianing Fu; Kelley Haarberg; Claudio Anasetti; Amer A Beg; Xue-Zhong Yu
Journal:  Eur J Immunol       Date:  2013-07-04       Impact factor: 5.532

Review 9.  Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.

Authors:  Kelli P A MacDonald; Geoffrey R Hill; Bruce R Blazar
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

10.  Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease.

Authors:  Xiao Chen; Sanja Vodanovic-Jankovic; Bryon Johnson; Melissa Keller; Richard Komorowski; William R Drobyski
Journal:  Blood       Date:  2007-08-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.